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Background: Approval for the use of COVID-19 vaccines has been granted in a
number of countries but there are concerns that vaccine uptake may be low amongst
certain groups.
Methods: This study used a mixed methods approach based on online survey and
an embedded quantitative/qualitative design to explore perceptions and attitudes that
were associated with intention to either accept or refuse offers of vaccination in different
demographic groups during the early stages of the UK’s mass COVID-19 vaccination
programme (December 2020). Analysis used multivariate logistic regression, structural
text modeling and anthropological assessments.
Results: Of 4,535 respondents, 85% (n = 3,859) were willing to have a COVID-19
vaccine. The rapidity of vaccine development and uncertainties about safety were
common reasons for COVID-19 vaccine hesitancy. There was no evidence for the
widespread influence of mis-information, although broader vaccine hesitancy was
associated with intentions to refuse COVID-19 vaccines (OR 20.60, 95%CI 14.20–30.30,
p < 0.001). Low levels of trust in the decision-making (OR 1.63, 95% CI 1.08, 2.48,
p = 0.021) and truthfulness (OR 8.76, 95% CI 4.15–19.90, p < 0.001) of the UK
government were independently associated with higher odds of refusing COVID-19
vaccines. Compared to political centrists, conservatives and liberals were, respectively,
more (OR 2.05, 95%CI 1.51–2.80, p < 0.001) and less (OR 0.30, 95% CI 0.22–0.41, p
< 0.001) likely to refuse offered vaccines. Those who were willing to be vaccinated cited
both personal and public protection as reasons, with some alluding to having a sense of
collective responsibility.
Conclusion: Dominant narratives of COVID-19 vaccine hesitancy are misconceived
as primarily being driven by misinformation. Key indicators of UK vaccine acceptance
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include prior behaviors, transparency of the scientific process of vaccine development,
mistrust in science and leadership and individual political views. Vaccine programmes
should leverage the sense of altruism, citizenship and collective responsibility that
motivated many participants to get vaccinated.
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INTRODUCTION
In December 2020, the United Kingdom became the first
country to approve the use of a vaccine directed against
SARS-Cov-2 after successful trials of the Pfizer/BioNTech
BNT162b2mRNA vaccine (1). Regulatory approval of the Oxford
University/AstraZeneca ChAdOx1 (2) and Moderna mRNA-
1273 (3) products brought two additional vaccines to the UK
market by early January 2021. Immediately after the licensing
of BNT162b2, the UK government commenced an ambitious
national vaccination campaign that aimed to maximize the short-
term impacts by (1) leveraging the probability that there would
be high levels of efficacy from a single dose of (any available)
COVID-19 vaccine and (2) by delivering available vaccine to
older and clinically vulnerable individuals first (4). The UK’s
gamble on the effectiveness of a single dose was vindicated by
subsequent evidence that a single dose of BNT162b2 was highly
protective against emergency hospitalization and mortality,
whilst a single dose of ChAdOx1 similarly protected from severe
disease (5). Early findings from passive surveillance of household
transmission in England (6) also showed that vaccination was
associated with a reduced secondary attack rate, suggesting that
vaccinated people who contracted SARS-CoV-2 infections were
less able to transmit infection than unvaccinated people (7).
The UK’s vaccination strategy and programme has been hailed
a success, with three-quarters of all UK adults having received
at least one dose of a SARS-CoV-2 vaccine and 50% having
received two doses by 2021-03-17 (8). This figure is somewhat
higher than the estimates of a June 2020 survey of around 13,000
people in 19 countries, which reported that on average 71% of
respondents were either likely or very likely to accept a SARS-
CoV-2 vaccine. The very high uptake of SARS-CoV-2 vaccines in
the UK appears to indicate a substantial increase in SARS-CoV-2
vaccine confidence and also seems to fly in the face of both (1)
that these vaccines remain mostly uncharacterised for long-term
safety and (2) that there has been a recent national and global
trend of vaccine hesitancy for a range of vaccines (9) which has
emerged as one of the most significant and complex public health
challenges of the twenty-first century.
The WHO SAGE Working Group on Vaccine Hesitancy
previously developed the “3 Cs” model of vaccine hesitancy (10)
which describes three key factors [Confidence, Complacency,
Convenience] that contribute to vaccine hesitancy. The success
of the UK’s SARS-CoV-2 vaccination strategy can potentially
be explained as having made the process of vaccination highly
convenient by making a sufficient number of vaccine doses
available through the National Health Service (NHS), at local
health centers and at zero cost to the public. The level of
complacency is also likely to be very low because of the highly
visible personal, social, cultural, economic and global impacts
of the pandemic. The drivers and extent of UK confidence in
SARS-CoV-2 vaccines are however more debatable (11) and in
this work we aim to understand how individuals living in the UK
made decisions about their intentions to either accept or refuse
vaccination at the very beginning of the UK national vaccination
programme that commenced in December 2020. In order to
achieve this goal we carried out an online survey of ∼4,500
adults living in the UK and applied an embeddedmixed-methods
approach to analysis and interpretation.
MATERIALS AND METHODS
Ethics Approval and Consent to Participate
This study was approved by the research ethics committees of the
London School of Hygiene & Tropical Medicine (ref: 17860) and
World Health Organization (ref: CERC.0039B). The data were
fully anonymous and the study team were unable to identify any
respondents. The respondents provided informed consent at the
start of the survey by means of ticking a box on the web-form. All
questions in the survey were optional, meaning that participants
could skip questions if they did not want to divulge specific data.
Survey Design
We designed and deployed an embedded mixed-methods online
survey as previously described (12). Briefly, the survey included
both quantitative and qualitative (open-ended text) questions
that were relevant to the UK COVID-19 outbreak, COVID-19
vaccines and their relationship to participants’ health, health
behaviors and attitudes. All data were collected anonymously
and securely using ODK (13). The survey was advertised using
Facebook’s premium “Boost Post” feature (14) and ran from
2020-12-08 to 2020-12-16. All questions in the survey were
voluntary, meaning that participants could skip questions that
they did not wish to answer. Adverts were targeted to the eligible
population of people aged 18 and over and living in the UK.
All participants were asked to provide informed consent and to
confirm their eligibility.
The survey included questions on the topics of (1)
Demographics, (2) Compliance with testing and isolation
following COVID-19 symptoms, (3) Use of the NHS COVID-
19 contact tracing app, (4) Trust in the government and their
decision making, (5) Health condition and exercise, (6) Domestic
and gender-based violence and (7) Attitudes toward vaccination.
Study respondents were asked “When COVID-19 vaccines
become available, will you be happy to get vaccinated?” [Yes
| No], “Why would/wouldn’t you get vaccinated?” [Free text]
and “Which of these best describes your general feelings about
vaccines?” [I believe that vaccines are an effective way to control
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infectious diseases | I have concerns about the usefulness of
some or all vaccines, but have not turned down the offer of
vaccination for me or a member of my household | I have
concerns about the usefulness of some or all vaccines and have
previously turned down one or more offers of vaccination for
me or a member of my household]. To gauge previous vaccine
seeking behaviors, we asked participants “Do you get a seasonal
flu vaccine?” [Always/Usually | Sometimes | Never]. Participants
indicated if they were disabled as described in section 6 of the
UK Equality Act 2010 [Yes | No] and provided a self-assessment
of their general health over the last 4 weeks [Very bad | Bad | Fair
| Good | Very good].
Respondents were further asked “Do you think that the UK
government (Westminster) is making good decisions about how
to control COVID-19?” [Yes/No], “Do you think that the UK
government tells you the whole truth about coronavirus and
COVID-19” [Always | Mostly | Sometimes | Almost never |
Never | I don’t know] and “Do you feel that your household has
experienced financial hardship as a result of COVID-19” [Yes
| No].
Demographic variables included in the analysis were age
group [18–29 years, 30–49 years, 50–69 years, and 70+],
gender [Female | Male | Another gender], highest educational
attainment [GCSEs/O-levels | A levels/Highers | Degree or
higher degree], ethnicity [using UK Government 2011 census
groups (15)] employment [Full time | Part time | Home-
maker | Retired | Student | Unemployed], annual household
income [Less than £15,000 | £15,000–£24,999 | £25,000–£39,999 |
£40,000–£59,999 | £60,000–£99,999 | £100,000+], political views
[Conservative/Right” | Floating/Centre | Liberal/Left] and UK
postcode area. Participants also provided information onwhether
they had prior doctor-diagnoses of several medical conditions
including asthma, cancer, type 1 and 2 diabetes, heart disease,
hypertension, lung disease, obesity, stroke, depression, and
anxiety. To assess recent signs of acute depression, participants
were asked “How often did you feel down, depressed, or hopeless
in the past 4 weeks [Not at all | less than half the time | More than
half the time | Every day].
Analysis
Analysis was performed using R version 4.0.3. Missing data
were imputed using the R package “mice” (16). For downstream
analysis, 15 imputed data sets were pooled using the R package
“sjmisc” to find the modal value for each missing data point.
The number of survey responses from ethnic minority groups
was low and for statistical purposes we categorized ethnicity
into two classes [White | Ethnic minority]. Acute depression was
classified as none [Not at all], mild [less than half the time]
and moderate-severe [More than half the time | Every day].
Univariate binomial logistic regression was used to determine
whether there was evidence for an association between each
variable and the outcome of vaccine acceptance. Any variable that
was significantly associated (after false discovery correction for
multiple testing) with vaccine acceptance decisions in univariate
analysis (Q < 0.05) was then included in a multivariate binomial
logistic regression analysis.
Topic Modeling
Structural topic modeling (STM) of open-ended text was used
to identify key topics associated with acceptance and non-
acceptance of a COVID-19 vaccine using the R package “stm”
(17). Free text responses to the question “Why would/wouldn’t
you accept a COVID-19 vaccine?” were processed into
separate text corpuses [accept/refuse] and analyzed individually.
Common stop-words (and, is, don’t, can’t etc.) and semantically
neutral words such as “COVID” and “Vaccine” were removed.
The number of topics that were included in each analysis was
determined from visualization of charts comparing several key
indicators provided by the STM process, including semantic
coherence (e.g., the clarity of topics), held-out likelihood (e.g.,
likelihood of retaining documents in the analysis) and minimal
residuals of the model fit. When identifying the optimal number
of topics to include in the analysis, we sought to maximize
the held-out likelihood (number of documents retained) whilst
minimizing the residuals. STM assigned a set of scores (theta
scores) to each free-text response or “quote” in the corpus and
these scores could be used to assign each quote to one or more of
the topics. We extracted the highest scoring quotes (theta > 0.3)
for each topic and used a lazy-consensus approach to defining
the topic names that we felt best described the content of the
group of quotes that had been assigned to each topic. A list of
the most frequent words used within the quotes assigned to each
topic was produced, along with a correlation matrix showing
the relationships between topics based on the correlation of the
maximum a posteriori estimates for the topic proportions. STM
topics with correlation>0.25 were grouped together as subtopics
of a single topic. Topics which were assigned fewer than five
quotes with theta >0.3 were not included in the analysis.
The STM process was performed once for the corpus of quotes
provided by those who said that they would accept a COVID-19
vaccine, then separately for the corpus provided by those who
intended to refuse a vaccine.
Qualitative Analysis
In each of the two STM analyses, we extracted those quotes
that had theta scores above 0.3. This approach was taken on the
assumptions that (1) quotes with a high theta score for a specific
topic were likely to be highly representative of the topic and (2)
that these quotes were unlikely to have content crossover with
other topics because the high theta score was proportional to high
exclusivity (noting that the individual topic theta scores for each
quote always add to 1.0). Detailed thematic qualitative analysis
then allowed us to perform a thorough and nuanced exploration
of the topic content and meanings.
RESULTS
The advert and survey were active between 2020-12-08 and 2020-
12-18. The total “reach” of the Facebook advert (i.e., the total
number of individuals to whom the advert was displayed at least
once) included 120,826 people living in England (n = 99,834),
Scotland (n = 10,368), Wales (n = 8,384), and Northern Ireland
(n= 2,240). The advert reached 69,115 females, 48,534 males and
2,176 people who did not declare their gender on Facebook. The
Frontiers in Public Health | www.frontiersin.org 3 November 2021 | Volume 9 | Article 745630
Roberts et al. UK COVID-19 Vaccine Confidence
link to the survey webpage was clicked 7,472 times (an overall
click-through rate of 0.0618 and cost per click £0.16). In total,
4,535 respondents completed the survey (overall conversion rate
from advert to survey completion 0.038, cost per survey response
£0.22). There was substantial heterogeneity in the click-through
and conversion rates among different age and gender groups.
Demographically, the cohort had notably high levels of
representation from females (65%), people aged 50–69 (61%)
and people who were educated to degree level or higher (55%).
The survey had very low representation of ethnic minority
groups (3%) which is in keeping with our findings in a previous
(similarly designed) survey (12, 18). Other demographic factors
including postcode areas, income and employment were more
evenly represented in the cohort (Table 1). The respondents were
located in England (n= 3,910, 86.2%), Scotland (n= 316, 7.0%),
Wales (n= 263, 5.8%), and Northern Ireland (n= 46, 1.0%).
Overall, 85% (3859/4535) of participants indicated that they
would accept a SARS-CoV-2 vaccine if offered one. Table 1
provides a summary of the survey’s demographic data and the
results of both the univariate and multivariate logistic regression
tests. Showing only those variables where there were significant
differences between the groups in multivariate analysis, Figure 1
illustrates the odds ratios and associated confidence intervals of
intending to reject an offer of a COVID-19 vaccine in different
groups who took part in the study.
The STM analysis identified 16 topics (REF01–REF16) that
together described the key reasons given for refusing a COVID-
19 vaccine (Table 2). Topic REF16 had too few quotes and
was dropped from the analysis. A further 16 topics (ACC01-
ACC16) were identified for the group who intended to accept
COVID-19 vaccination (Table 3). Seven sub-topics (ACC02ii,
ACC04iii, ACC04v, ACC05i, ACC05ii, ACC05iii, and ACC05v)
had fewer than five quotes with theta >0.3 and were dropped
from the analysis.
Government Decisions
We found that just 21.7% (n= 982) of study participants thought
that the UK government was making good decisions about the
control of COVID-19. After adjusting for all covariates in a
multivariate regression analysis (Figure 1 and Table 1), the odds
ratios of COVID-19 vaccine refusal were found to be higher
amongst those who did not believe that the UK government was
making good decisions about the COVID-19 response (OR 1.63,
95% CI 1.08–2.48, p= 0.021).
In topic ACC06, respondents expressed how their intention
to be vaccinated was informed by their strong trust in science,
the NHS, scientists and scientific method. These respondents
were not equally positive about the role of the UK government
and some made it clear that although they had doubts
about the government’s role, this did not deter them from
accepting vaccines.
“Although I have little faith in the government, I do have faith in
the UK’s medical approval authorities and processes”
“I trust science, and our NHS, despite the government’s
manipulation of the situation.”
Among the quotes from potential vaccine refusers, criticisms
of the government were generally focussed on questions
surrounding their motivations, truthfulness and political or
social agenda.
Government Trust
Nearly one third of respondents (29.7%, n= 1,344) believed that
the UK government never, or almost never, told the whole truth
about coronavirus and COVID-19. The odds ratios of COVID-19
vaccine refusal were higher amongst those who thought that the
UK government “never” (OR 8.76, 95% CI 4.15–19.9, p < 0.001)
or “almost never” (OR 4.79, 95% CI 2.31–10.73, p < 0.001) told
the whole truth about COVID-19.
In topic REF02, participants expressed their skepticism about
the UK government’s role in the very rapid process of COVID-
19 vaccine development. Many of the respondents whose quotes
made up topics REF02 and REF03 felt that it was hard to believe
that a valid and legitimate process could be completed in such a
short time.
“Not enough testing (8–12 months compared to 8–12 years for
normal vaccine development), too much secrecy regarding content
and method of production, problems arising even in early cases.”
“I religiously get my flu jab each year, and have had numerous other
vaccinations throughout my life—the only negative experience was
when I was in the NHS in the 1980s when Hep C jabs were being
promoted that had been formulated from Us [USA] blood products,
but this has not stopped me having all the other proven vaccines
above....However re COVID-19:- I’m not convinced by the lack of
studies of long term effects; need to know more about differences
between the vaccines; interested to know how theMHRA had all the
info re Pfizer, when the final results were released a week after they
had said it was okay; the optics of share sales (moderna)/efficacy
results changing within hours of a share price crash (astra zeneca)
are not altogether encouraging either.”
These concerns appeared to reflect suspicions that were implicitly
leveled at both the government (REF02) and pharmaceutical
companies (REF10).
“Because the medical profession tell us that it takes between five and
ten years to perfect a good vaccine, we are being told that Pfizer, has
done this in six months. Garbage.”
“Please! If a cure couldn’t be found for Coronovirus or the
other cold viruses since research started in 1947, then ergo, these
’vaccines’ have obviously already been manufactured well before the
’pandemic’. My question is...Why?”
Others were suspicious not only of the timeline of development,
but also of the potential for personal financial gain for ministers
and the alleged provision by the government of legal indemnities
to pharmaceutical companies.
“No confidence or trust whatsoever in the testing regimes for the
vaccines. If they are so good why has [the] government given
immunity from prosecution in the event of adverse reactions to big
pharma companies?”
































TABLE 1 | Sample characteristics, univariate, and multivariate analyses.
Univariate analysis Multivariate analysis
Characteristic Total








(N = 676) n%
††
ORa 95% CIa p-value q-valueb ORa 95% CIa p-value
Gender 0.001 0.002
Female 2,983 (65.8%) 2,577 (86.4%) 406 (13.6%) — — — —
Male 1,527 (33.7%) 1,264 (82.8%) 263 (17.2%) 1.32 1.11, 1.56 1.23 0.94, 1.61 0.13
Other genders 25 (0.6%) 18 (72.0%) 7 (28.0%) 2.47 0.95, 5.70 1.05 0.25, 4.03 >0.9
Age <0.001 <0.001
18–34 149 (3.3%) 122 (81.9%) 27 (18.1%) — — — —
35–54 1,375 (30.3%) 1,096 (79.7%) 279 (20.3%) 1.15 0.75, 1.81 1.14 0.57, 2.34 0.7
55–69 2,222 (49.0%) 1,914 (86.1%) 308 (13.9%) 0.73 0.48, 1.14 0.96 0.47, 2.03 >0.9
70+ 789 (17.4%) 727 (92.1%) 62 (7.9%) 0.39 0.24, 0.64 0.55 0.24, 1.30 0.2
Education <0.001 <0.001
School 878 (19.4%) 709 (80.8%) 169 (19.2%) — — — —
Further 1,173 (25.9%) 980 (83.5%) 193 (16.5%) 0.83 0.66, 1.04 1.06 0.74, 1.51 0.7
Higher 2,484 (54.8%) 2,170 (87.4%) 314 (12.6%) 0.61 0.49, 0.75 1.29 0.92, 1.81 0.14
Employment <0.001 <0.001
Full time 1,275 (28.1%) 1,036 (81.3%) 239 (18.7%) — — — —
Part time 774 (17.1%) 651 (84.1%) 123 (15.9%) 0.82 0.64, 1.04 1 0.70, 1.43 >0.9
Retired 1,987 (43.8%) 1,789 (90.0%) 198 (10.0%) 0.48 0.39, 0.59 0.63 0.43, 0.92 0.016
Student 65 (1.4%) 53 (81.5%) 12 (18.5%) 0.98 0.49, 1.80 1.8 0.66, 4.53 0.2
Homemaker 231 (5.1%) 171 (74.0%) 60 (26.0%) 1.52 1.09, 2.10 1.29 0.79, 2.09 0.3
Unemployed 203 (4.5%) 159 (78.3%) 44 (21.7%) 1.2 0.83, 1.71 0.68 0.38, 1.18 0.2
Disabled 0.003 0.005
No 4,044 (89.2%) 3,464 (85.7%) 580 (14.3%) — — — —
Yes 491 (10.8%) 395 (80.4%) 96 (19.6%) 1.45 1.14, 1.84 1.44 0.96, 2.14 0.071
Ethnicity 0.002 0.003
White 4,388 (96.8%) 3,748 (85.4%) 640 (14.6%) — — — —
Ethnic minority 147 (3.2%) 111 (75.5%) 36 (24.5%) 1.9 1.28, 2.76 1.23 0.65, 2.24 0.5
COVID-19 symptoms <0.001 <0.001
No 3,525 (77.7%) 3,037 (86.2%) 488 (13.8%) — — — —
Yes 1,010 (22.3%) 822 (81.4%) 188 (18.6%) 1.42 1.18, 1.71 1.15 0.86, 1.51 0.3
Believes UK government is making good
decisions about COVID-19 control
<0.001 <0.001
Yes 982 (21.7%) 929 (94.6%) 53 (5.4%) — — — —




















































































TABLE 1 | Continued
Univariate analysis Multivariate analysis
Characteristic Total








(N = 676) n%
††
ORa 95% CIa p-value q-valueb ORa 95% CIa p-value
Believes UK government tells the truth
about COVID-19 and Coronavirus
<0.001 <0.001
Always 195 (4.3%) 183 (93.8%) 12 (6.2%) — — — —
Mostly 1,581 (34.9%) 1,526 (96.5%) 55 (3.5%) 0.55 0.30, 1.09 0.6 0.29, 1.32 0.2
Sometimes 1,415 (31.2%) 1,272 (89.9%) 143 (10.1%) 1.71 0.97, 3.32 1.65 0.81, 3.65 0.2
Almost never 842 (18.6%) 641 (76.1%) 201 (23.9%) 4.78 2.72, 9.23 4.79 2.31, 10.7 <0.001
Never 502 (11.1%) 237 (47.2%) 265 (52.8%) 17.1 9.66, 33.0 8.76 4.15, 19.9 <0.001
Overall health (Self-assessed) <0.001 <0.001
Very good 1,347 (29.7%) 1,071 (79.5%) 276 (20.5%) — — — —
Good 1,967 (43.4%) 1,736 (88.3%) 231 (11.7%) 0.52 0.43, 0.62 0.64 0.48, 0.85 0.002
Fair 947 (20.9%) 839 (88.6%) 108 (11.4%) 0.5 0.39, 0.63 0.45 0.31, 0.66 <0.001
Bad 226 (5.0%) 180 (79.6%) 46 (20.4%) 0.99 0.69, 1.40 0.63 0.36, 1.09 0.11
Very bad 48 (1.1%) 33 (68.8%) 15 (31.2%) 1.76 0.92, 3.24 1 0.36, 2.58 >0.9
Signs of depression in last 4 weeks <0.001 <0.001
Not at all 1,435 (31.6%) 1,235 (86.1%) 200 (13.9%) — — — —
Several days 1,730 (38.1%) 1,535 (88.7%) 195 (11.3%) 0.78 0.64, 0.97 0.94 0.69, 1.29 0.7
Half the days 970 (21.4%) 807 (83.2%) 163 (16.8%) 1.25 1.00, 1.56 1.09 0.77, 1.54 0.6
Every day 400 (8.8%) 282 (70.5%) 118 (29.5%) 2.58 1.99, 3.35 1.27 0.82, 1.96 0.3
Smoking in the last 4 weeks <0.001 <0.001
None 4,070 (89.7%) 3,525 (86.6%) 545 (13.4%) — — — —
Light 198 (4.4%) 148 (74.7%) 50 (25.3%) 2.19 1.55, 3.03 1.33 0.78, 2.21 0.3
Moderate 208 (4.6%) 150 (72.1%) 58 (27.9%) 2.5 1.81, 3.41 1.01 0.60, 1.66 >0.9
Heavy 59 (1.3%) 36 (61.0%) 23 (39.0%) 4.13 2.40, 6.98 2.84 1.25, 6.27 0.011
Type 1 diabetes 0.54 0.62
No 4,448 (98.1%) 3,783 (85.0%) 665 (15.0%) — —
Yes 87 (1.9%) 76 (87.4%) 11 (12.6%) 0.82 0.41, 1.49
Type 2 diabetes 0.036 0.052
No 4,044 (89.2%) 3,426 (84.7%) 618 (15.3%) — —
Yes 491 (10.8%) 433 (88.2%) 58 (11.8%) 0.74 0.55, 0.98
Asthma 0.3 0.38
No 3,520 (77.6%) 2,985 (84.8%) 535 (15.2%) — —
Yes 1,015 (22.4%) 874 (86.1%) 141 (13.9%) 0.9 0.73, 1.10
Lung disease 0.25 0.33
No 4,233 (93.3%) 3,609 (85.3%) 624 (14.7%) — —




















































































TABLE 1 | Continued
Univariate analysis Multivariate analysis
Characteristic Total








(N = 676) n%
††
ORa 95% CIa p-value q-valueb ORa 95% CIa p-value
Cancer 0.32 0.39
No 4,029 (88.8%) 3,421 (84.9%) 608 (15.1%) — —
Yes 506 (11.2%) 438 (86.6%) 68 (13.4%) 0.87 0.66, 1.14
Stroke 0.12 0.17
No 4,351 (95.9%) 3,710 (85.3%) 641 (14.7%) — —
Yes 184 (4.1%) 149 (81.0%) 35 (19.0%) 1.36 0.92, 1.96
Heart disease 0.73 0.76
No 4,128 (91.0%) 3,515 (85.2%) 613 (14.8%) — —
Yes 407 (9.0%) 344 (84.5%) 63 (15.5%) 1.05 0.79, 1.38
Hypertension <0.001 <0.001
No 3,092 (68.2%) 2,580 (83.4%) 512 (16.6%) — — — —
Yes 1,443 (31.8%) 1,279 (88.6%) 164 (11.4%) 0.65 0.53, 0.78 0.89 0.66, 1.21 0.5
Obesity <0.001 <0.001
No 3,755 (82.8%) 3,161 (84.2%) 594 (15.8%) — — — —
Yes 780 (17.2%) 698 (89.5%) 82 (10.5%) 0.63 0.49, 0.79 0.99 0.69, 1.40 >0.9
Depression (doctor diagnosed) 0.65 0.69
No 3,058 (67.4%) 2,597 (84.9%) 461 (15.1%) — —
Yes 1,477 (32.6%) 1,262 (85.4%) 215 (14.6%) 0.96 0.80, 1.14
Anxiety 0.99 0.99
No 3,192 (70.4%) 2,716 (85.1%) 476 (14.9%) — —
Yes 1,343 (29.6%) 1,143 (85.1%) 200 (14.9%) 1 0.83, 1.19
General feelings about vaccines and
vaccination
<0.001 <0.001
No vaccine concerns 3,658 (80.7%) 3,435 (93.9%) 223 (6.1%) — — — —
Vaccine concerns 521 (11.5%) 352 (67.6%) 169 (32.4%) 7.4 5.88, 9.29 3.56 2.67, 4.75 <0.001
Vaccine concerns and rejected vaccine offers 356 (7.9%) 72 (20.2%) 284 (79.8%) 60.8 45.6, 81.9 20.6 14.2, 30.3 <0.001
Previous flu vaccine behaviors <0.001 <0.001
Always/Usually gets flu vaccine 2,725 (60.1%) 2,610 (95.8%) 115 (4.2%) — — — —
Sometimes gets flu vaccine 751 (16.6%) 637 (84.8%) 114 (15.2%) 4.06 3.09, 5.34 1.89 1.34, 2.66 <0.001
Does not get flu vaccine 1,059 (23.4%) 612 (57.8%) 447 (42.2%) 16.6 13.3, 20.8 5.39 4.01, 7.29 <0.001
Household income <0.001 <0.001
Less than £15,000 595 (13.1%) 467 (78.5%) 128 (21.5%) — — — —
£15,000–£24,999 908 (20.0%) 756 (83.3%) 152 (16.7%) 0.73 0.56, 0.95 0.66 0.44, 0.98 0.041
£25,000–£39,999 1,183 (26.1%) 1,011 (85.5%) 172 (14.5%) 0.62 0.48, 0.80 0.69 0.46, 1.03 0.068




















































































TABLE 1 | Continued
Univariate analysis Multivariate analysis
Characteristic Total








(N = 676) n%
††
ORa 95% CIa p-value q-valueb ORa 95% CIa p-value
£60,000–£99,999 684 (15.1%) 595 (87.0%) 89 (13.0%) 0.55 0.40, 0.73 0.42 0.26, 0.68 <0.001
More than £100,000 270 (6.0%) 233 (86.3%) 37 (13.7%) 0.58 0.38, 0.85 0.40 0.21, 0.75 0.005
Suffered financial hardship during
pandemic (Self-assessed)
<0.001 <0.001
no 3,591 (79.2%) 3,140 (87.4%) 451 (12.6%) — — — —
yes 944 (20.8%) 719 (76.2%) 225 (23.8%) 2.18 1.82, 2.60 1.02 0.76, 1.36 0.9
Political opinions <0.001 <0.001
Floating 1,471 (32.4%) 1,173 (79.7%) 298 (20.3%) — — — —
Conservative 1,080 (23.8%) 853 (79.0%) 227 (21.0%) 1.05 0.86, 1.27 2.05 1.51, 2.80 <0.001
Liberal 1,984 (43.7%) 1,833 (92.4%) 151 (7.6%) 0.32 0.26, 0.40 0.3 0.22, 0.41 <0.001
Postcode area 0.55 0.62
London 436 (9.6%) 374 (85.8%) 62 (14.2%) — —
East Midlands 366 (8.1%) 317 (86.6%) 49 (13.4%) 0.93 0.62, 1.39
East of England 461 (10.2%) 401 (87.0%) 60 (13.0%) 0.9 0.62, 1.32
North East 361 (8.0%) 314 (87.0%) 47 (13.0%) 0.9 0.60, 1.35
North West 515 (11.4%) 426 (82.7%) 89 (17.3%) 1.26 0.89, 1.80
Northern Ireland 46 (1.0%) 36 (78.3%) 10 (21.7%) 1.68 0.75, 3.44
Scotland 316 (7.0%) 260 (82.3%) 56 (17.7%) 1.3 0.87, 1.93
South East 644 (14.2%) 553 (85.9%) 91 (14.1%) 0.99 0.70, 1.41
South West 482 (10.6%) 409 (84.9%) 73 (15.1%) 1.08 0.75, 1.56
Wales 263 (5.8%) 226 (85.9%) 37 (14.1%) 0.99 0.63, 1.53
West Midlands 345 (7.6%) 291 (84.3%) 54 (15.7%) 1.12 0.75, 1.66
Unknown 300 (6.6%) 252 (84.0%) 48 (16.0%) 1.15 0.76, 1.73
























































Roberts et al. UK COVID-19 Vaccine Confidence
FIGURE 1 | Intention to refuse offers of COVID-19 vaccination among members of the UK public. Odds ratio (OR) estimates [points] and 95% confidence intervals
[solid lines] indicate relative intention to refuse vaccine. ORs above 1.00 indicate increased OR of rejecting vaccines. Values below 1.00 indicate increased intention to
accept vaccines. All ORs are fully corrected for other covariates. Covariates that had no significant association with intention to vaccinate are not shown, but are fully
described in Table 1.
“Rushed, not properly tested vaccines from companies where there
is personal financial gain for govt ministers and friends, also the
granting of immunity against liability for adverse drug reactions to
all who are developing vaccines, they have been trying to develop
a corona virus [sic] vaccine for over 20 years, without success, now
suddenly the miracle happens?”
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Some also questioned whether there was any real need to
vaccinate the population when COVID-19 was a relatively mild
disease in the majority of people and had a low overall mortality
rate (REF04).
“the virus is mostly a mild disease. Statistics for Covid don’t support
general vaccination.”
“To bring the country to a standstill over a virus with a 98%
recovery rate and a death rate one year above the national life
expectancy I believe the reaction to it has been grossly over the top
I therefore it goes against every sinew in me to get the vaccine I am
not scared of the virus and would rather my body battle it naturally
and I’m not prepared to have have something that has been rushed
through with unknown long-term or short-term side effects put into
my body”
“This is a [sic] untested RNA vaccine. Knowone [sic] knows the long
terms [sic] effects of this. Plus this virus has a 99.8% survival rate.
Therefore, vaccines are not needed”
“Too soon to assess effectiveness or side effects. Plus the virus
is mostly a mild disease. Statistics for Covid don’t support
general vaccination.”
Confidence in Vaccines
The majority of respondents always or usually had a yearly
vaccination against influenza virus (n = 2,725, 60.1%).
Individuals who reported either never (OR 5.39, 95% CI 4.01–
7.29, p < 0.001) or only sometimes (OR 1.89, 95% CI 1.34–
2.66, p < 0.001) having a seasonal influenza vaccine were less
likely to accept COVID-19 vaccines than those who did so every
year. Members of both groups described how they informed
their decisions with reference to their use or experiences of flu
vaccines. On the side of those who would accept COVID-19
vaccines, topic ACC01 included comments that indicated how
some participants saw little difference between the COVID-19
vaccines and those they already used for flu.
“I sometimes have the flu jab. Same difference to me”
“Same reason I have a flu jab every year–to avoid getting the virus”
Some participants who planned to get vaccinated (ACC15)
reflected on the maxim that “Prevention is better than cure” and
cited the successes of previous vaccination campaigns
“When I was young polio was common and life threatening.
Vaccination changed all that. Presumably this vaccination will do
the same for Covid.”
“the only disease to be eradicated is small pox [sic] the rest are
managed by better treatments and vaccines”
Meanwhile in the other group (REF07), some participants
reflected on their own negative experiences of flu vaccines,
focussing on their perceptions of how these had previously
harmed their health.
TABLE 2 | Topics summarizing reasons for intending to refuse a COVID-19
vaccine.
Topica Title n.0.3b
REF01 Healthy, so can rely on own immune system 25
REF02i No trust in government, pharma industry and
vaccine
6
REF02ii Mistrust of pharma and government in context
of rapid development of vaccines
21
REF02iii Vaccines have not been tested enough 22
REF02iv Not enough testing, specific concerns of
adverse reactions and unforeseen
complications
12
REF03 Concerns about unknown safety and
effectiveness
11
REF04 Lack of need for COVID-19 vaccine given low
overall mortality rate
18
REF05 Undecided and/or concerned about
side-effects and personal medical history
21
REF06 Risks of relatively untested vaccine vs. benefits
of vaccinating generally healthy people
10
REF07 Contextualizes COVID-19 vaccines in personal
history of flu vaccines and adverse reactions
19
REF08i Concerns about side effects 6
REF08ii Concerns about long term side effects 16
REF09 Previous bad reactions to vaccines and/or
allergies to penicillin
18
REF10 Concerned about quality of research during
rapid vaccine development
25
REF11 Pregnant, breastfeeding, ineligible or unwilling
to be vaccinated
13
REF12 Potentially willing to be vaccinated, but
expressed hesitancy or concerns
29
REF13 Allergies and reactions to medicines 24
REF14 References to previously failed trials, legal
cases and medical scandals
9
REF15 Ethical or medical concerns about derivation,
formulation and effects of vaccine
12
REF16 [Fewer than five quotes with theta > 0.3] 4
aRoman numerals indicate sub-topics with correlation > 0.2.
bn.0.3 Number of quotes assigned to topic with theta score > 0.3.
“The flu jab caused m.e [myalgic encephalitis] in 2009. I want to
build my exposure naturally as when my health improves I will be
back at the allotment [a plot of land rented by an individual for
growing vegetables]. I understand a small part of virus helps your
body fight and remember how to fight in future. I just question what
else is in them now. People have glandular fever and are ok. I think
it was that and the combination of the vaccine that didn’t give my
body a chance. My nanny has also recently said. Bare [sic] in mind
she’s 80 she doesn’t feel so well after this recently [sic] flu jab and
isn’t recovering. . . ”
“I had my 1 and only Flu jab back in 1974 and suffered the worst
bout of Flu soon after, 5 weeks off work, over 1 stone lost in weight.
I’ve not had a Flu jab in the ensuing 46 years, and I’ve never had the
Flu since either, so no, I will not be having the Covid-19 vaccine!”
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TABLE 3 | Topics summarizing reasons for intending to accept a COVID-19
vaccine.
Topica Title n.0.3b
ACC01 Recognizes value of vaccinations and
compares COVID-19 to flu vaccines
37
ACC02i Wants to get back to normal life >100
ACC02ii [Fewer than five quotes with theta > 0.3] 1
ACC03 Aware of risks and concerns of others, but on
balance sees benefit of COVID-19 vaccines
39
ACC04i Wants to protect loved ones / vulnerable
people, and travel to see friends and family
55
ACC04ii Protect self and others 7
ACC04iii [Fewer than five quotes with theta > 0.3] 1
ACC04iv Wishes to mix in social, cultural and work
contexts
7
ACC04v [Fewer than five quotes with theta > 0.3] 0
ACC05i [Fewer than five quotes with theta > 0.3] 0
ACC05ii [Fewer than five quotes with theta > 0.3] 0
ACC05iii [Fewer than five quotes with theta > 0.3] 2
ACC05iv To prevent contracting and spreading infection 8
ACC05v [Fewer than five quotes with theta > 0.3] 1
ACC06 Trusts the science, scientists and the scientific
process
52
ACC07 Has some concerns, but on balance believes
acceptance the correct choice
13
ACC08 To help build herd immunity 58
ACC09 Recognizes vaccination as a social
responsibility and public good
27
ACC10 Healthcare professionals and/or visit care
homes
20
ACC11 Responsibilities to the wider community 17
ACC12 Works in NHS, Schools, Pharma and with
vulnerable people
34
ACC13 Participant and/or family member in high risk
group because of age or medical condition
54
ACC14 Vaccination to be safe and make others safe,
some with negative sentiments on UK
government
10
ACC15 Prevention better than cure, referencing
success of historical vaccine programmes
13
ACC16 It is the sensible and responsible thing to do 72
aRoman numerals indicate sub-topics with correlation > 0.2.
bn.0.3 Number of quotes assigned to topic with theta score > 0.3.
The majority of participants (3,658, 80.7%) expressed general
confidence in vaccines. Among those who were vaccine hesitant,
521 (11.5%) had concerns about the usefulness of vaccines and a
further 356 (7.9%) not only shared these concerns, but had also
rejected some or all vaccines they had been offered in the past.
Participants who had concerns about vaccines in general and
who either had (OR 20.6, 95% CI 14.20–30.30, p < 0.001) or had
not (OR 3.56, 95% CI 2.67–4.75, p < 0.001) previously turned
down offers of vaccines against other diseases, were all more likely
to indicate intention to refuse COVID-19 vaccines. Participants
who planned to accept COVID-19 vaccines spoke of how they
recognized the value of vaccinations (ACC01, ACC05 & ACC14)
and of how they accepted that vaccination was a safe and effective
process that could help establish herd immunity (ACC08).
“I regard it as my personal contribution to the overall health of the
population. It is necessary for herd immunity in the true sense of
the phrase”
“Because herd immunity is essentially a myth: measles, TB,
polio, smallpox- none of these (and others) were ever eliminated
from a population by herd immunity [presumably meaning by
uncontrolled natural spread of infection], but by vaccination.”
A number of participants made the points (ACC16) that they felt
that vaccinating oneself was the “sensible and responsible” thing
to do, that (ACC11) these decisions reflected responsibilities to
dependents or the wider community in the pursuance of (ACC01
and ACC09) public good through (ACC09) common sense.
“Because it’s the right thing to do to see [an] end of how we are all
currently constrained”
“To protect myself, to reduce the amount of virus in the community,
to free myself from isolation”
“Because it’s stupid and irresponsible not to unless there’s a genuine
medical reason why you can’t.”
“We live in a society, each person in that society have [sic]
obligations to each other. By having the vaccine you are fulfilling
one of those obligations. Each and every person must do what is
needed to fight this pandemic no matter what it is otherwise we will
never get it under control.”
Some also stressed (ACC04) that vaccination would protect them
and others; including loved ones and social contacts who were
vulnerable. For many this was key to returning to normal life
(ACC02) and ending social distancing (ACC04).
“Protect myself and protect those that can’t be vaccinated. Hopefully
enable me to see friends and family again properly and hug them.
I haven’t hugged my mum, dad or friends since the start of March
and it really hurts.”
“I don’t want to get sick and I want my freedom back. I want
to see my children and friends, go to the movies or theatre,
travel. Have real galleries not online ones. Use public transport etc.
without fear.”
“it will be the only way to get life back to normal”
“I should like to live a normal life. I should like to go on holiday. I
should like to sing with other people. I live in London and I’d like to
use the Tube, go to the theatre, go to exhibitions.”
Among the group who planned to accept COVID-19 vaccines,
some mentioned that whilst they were not without concerns,
they had decided that on balance they could see a net benefit of
vaccination (ACC03 and ACC07).
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“I feel I probably should though I am nervous about how ’young’ the
vaccine is. I am aware all stages have been covered in development
but it has only been trialed/in use for a very short time. No one
has any idea of actual long term side effects. Most vaccines I’d have
would have been in use for years. What if we all regret it later?
Especially the newer RNA technology. I am more confident in the
Oxford style vaccine.”
“I don’t think any COVID vaccine will be completely safe as there’s
no decades worth of data to assess the long term consequences.
Howeve,r on balance, having the vaccine will be safer than
experiencing covid (or passing it on).”
Others who were willing to be vaccinated explained that
they would get vaccinated because they had roles as teachers,
healthcare workers or other frontline workers (some with
medical vulnerabilities) and/or regularly spent time with people
who were vulnerable or in care homes (ACC10 and ACC12).
“I work in healthcare and have severe asthma. I don’t want worse
lung function or to pass this on to vulnerable relatives and patients.
I want tier 3 [social distancing and lockdown] restrictions to end. I
don’t want more lockdowns.”
“I am vunerable [sic] due to my lung problems. The disease could
be fatal for me. I work with very vunerable patients. My mother in
law lives with us shes [sic] 85”
“I am on drugs that suppress my immune system and feel quite
vulnerable as I work in school where we can not socially distance
from the children”
Some participants who said they would refuse the offered
vaccines clarified that there were in fact circumstances under
which they would get vaccinated (REF12). For some, the need
to be vaccinated in order to be permitted to travel could be a
key influencing factor, whilst others wanted to wait to see longer
term effects in others. Still more said that they probably would
get vaccinated, but would not be “happy” about it (referencing
the specific wording of the survey question, see methods).
“I will if I’m coerced by the government to travel but I wouldn’t be
happy about it. I’d simply rather not and as I’m low on the list I
will wait.”
“Has only been tested on [a] small demographic. Company that
developed it [has] no vaccine experience. Will happily get London
[presumably University of Oxford/Astra-Zeneca] vaccine 2021 after
[it is] rolled out to [a] wider group. Plus had Covid recently so [my]
assumption is [that I] have antibodies at the moment.”
“I think it’s too soon/ quick-has [Prime Minister] boris [Johnson]
had it yet? I think it’ll be a while before I get called up so I’ll
reconsider then.”
Several topics (REF02, REF08, REF09, REF10, REF13, REF14)
meanwhile triangulated with a general mistrust of vaccines
and vaccine research. In topic REF08, participants expressed
concerns about the potential for long-term side effects or adverse
reactions, especially in the context of the track-records of various
pharmaceutical companies.
“No evidence that the “vaccine” would actually make a difference at
this stage and is unproven in the longer term. I am not statistically at
risk and therefore there appears to be more potential issues from the
vaccine than from the infection. As more data and evidence emerges
over time I will review this.”
“Because I don’t feel confident that there’s been an adequate
monitoring period after administration. Seeing politicians and the
CSO [Chief Scientific Officer] say they would have the vaccine whilst
it was still in phase 3 and unapproved destroyed my confidence in
it. Pfizer’s track record and the fact they have been granted legal
immunity also concerns me.”
“untested, unproven, vaccine manufacturers have been given
indemnity from prosecution for any harm the vaccine may cause,
developed far too fast by companies with a track record of fraud
and harm, no long term studies of a brand new vaccine type etc.”
“[I am] not convinced at the reassurances by all those involved with
their own agendas. Other vaccines have a history of out of court
settlements. There is no chance I would touch this vaccine for at
least 5–10 years.”
Further to comments indicating a general mistrust of
pharmaceutical companies (REF02), some quotes (REF13
and REF14) went on to reference notorious historical medical
scandals, including those related to the drugs Thalidomide
and Benoxaprofen.
“Approval too rushed. I grew up with Thalidomide victims
and was myself prescribed Opren [Benoxaprofen], which had to
subsequently be withdrawn.”
“Until the vaccine has been properly tested... I am of the
thalidomide generation... I would be very wary.”
Some participants either had personal experiences (REF09) of
adverse reactions to medicines or vaccines that had shaped their
opinions of COVID-19 vaccines, or were otherwise (REF15)
concerned that they could have reactions resulting from pre-
existing conditions.
“[I am] Slightly concerned and will take advice from GP as have
had allergic reaction to flu vaccine and penicillin in the past. More
than willing to have vaccine if reassured on likely adverse reaction.”
“I had a very bad reaction to a normal flu jab that resulted in going
to A&E due to dehydration. The symptoms I had are very similar
to the symptoms of covid”
“I have Lupus, Hughes Syndrome/APS/Antiphospholipid
Syndrome, Sjogrens, a slow thyroid/Hashimotos, Psoriatic
Arthropathy and STEVENS JOHNSON Disease, I have dire
reactions to drugs, and have an allergy to antibiotics, serious
allergies... so today we find out that people like me should not have
the Pfizer vac, I have had lot of vacs in my life but no more now.”
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Some participants also mentioned their ethical concerns about
derivation, formulation and effects of COVID-19 vaccines
(REF15, REF08, and REF09)
“Vaccines developed using aborted foetal cells are unethical. If there
is a vaccine that has been developed without using aborted foetal
cells in any part of the manufacture or testing processes, I would be
happy to receive that vaccine.”
“I react badly to vaccinations. The contents of them are more
harmful than the good they might do.”
“Will get oxford vaccine when licensed but I have concerns that the
Pfizer vaccine utilises muscle to make protein from rna [sic] and
that there is no long term back data to show whether this elicits any
side effects e.g.; autoimmune concerns or whether it is totally safe.
If I were 80 and high risk I would have it.”
Overall Health
Participants who rated their general health as ‘good’ (OR 0.45,
95% CI 0.31–0.66, p = 0.002), “fair” (OR 0.45, 95% CI 0.31–
0.66, p < 0.001) or “bad” (OR 0.63, 95% CI 0.36–2.58, p =
0.11) were all less likely to refuse COVID-19 vaccines than the
healthiest (“very good”) group. These effects were independent of
other covariates including age and pre-existing, doctor diagnosed
health conditions. In topic REF01, a number of participants who
intended to refuse offers of COVID-19 vaccines explained how
they felt they could rely on the strength of their healthy immune
system or health behaviors to protect them from COVID-19.
“Not tested long enough, insufficient test data available, Mnra
[sic] vaccine never been licenced before, no trust in the current
testing data, I look after myself, I eat well/healthy, exercise, good
immune system.”
“My diet and lifestyle are good good [sic] and hence immune system
is strong”
“I have an underlying health condition and vaccinations and
medications can compromise my immune system rather than
support it. I am not opposed to vaccinations, just cautious and
believe in supporting the immune system as much as possible
through diet, exercise [sic] and where necessary supplementation
i.e., vitamin D”
The concerns of some participants (REF05) reflected a position
where they may eventually decide to accept COVID-19 vaccines,
but only after further information became available. For some
this was guided by their personal medical concerns and overall
health, while others who were generally healthy (REF06) found
themselves trying to evaluate the risks of accepting a relatively
untested vaccine against the benefits of being vaccinated.
“[I have] Multiple autoimmune diseases, vaccine not tested on
people like me. No evidence that immune response to vaccine won’t
cause autoimmune flare or long term immune dysregulation. Not
an anti-vaxxer, just a chronic illness sufferer.”
“I am undecided, I would like to see more safety data as it is
rolled out.”
“I would like to see the result of studies into how long antibodies
last post vaccination and also learn more about how people are
reacting to it. So my answer is NO I won’t take it as soon as it
becomes available. By the time my turn comes my answer might
well be YES.”
“I do not take the flu jab either... but I also don’t take any other
medication unless it is essential. I do not feel that the long term
side effects of things like the flu jab or covid vaccine have been
fully investigated or understood. I expect that my usually quite good
immune system would handle a coronavirus- if it hasn’t already. It
may make sense for people who have been shown to be at higher risk
of complications to take the vaccine though. Also, I am pregnant
and the impact of the vaccine on fetuses has not been investigated.”
Others meanwhile considered themselves to be ineligible
because they belonged to special demographic categories (REF11
and REF13).
“I am breastfeeding. I will get vaccinated if it is safe for my baby or
when I stop breastfeeding.”
“Trying to get pregnant. I will be happy to get the vaccine once
more evidence is provided that it is not harmful to women trying
to conceive/pregnant”
“I would get vaccinated if I could trust the vaccine and am not
an anti vaccer [sic] but I have concerns about the current vaccine
in particular the warning to fertile or pregnant women as well
as breastfeeding mothers..... I am going to fit into one of these
categories for many yrs to come!”
“I suffer from an ongoing allergy problem and have to carry
adrenaline at all times. I understand that this means that I
cannot have the Pfizer vaccine. I’ll look at the others when they
are released.”
There was no evidence for a difference in COVID-19 vaccine
acceptance among groups with specific medical conditions (as
diagnosed by a doctor), those who were disabled, or who had
recent signs of depression. Ethnicity was not associated with
vaccine intention in this analysis, though we highlight the very
small number of respondents from ethnic minority groups and
lack of granularity in analysis of this variable. Heavy smokers
were also more likely to refuse (OR 2.84, 95% CI 1.25–6.27, p =
0.011) offered COVID-19 vaccines.
Employment Status and Income
We found that retirees were less likely to decline a COVID-19
vaccine compared to those in full time employment (OR 0.63,
95% CI 0.43–0.92, p = 0.016) but there was no evidence for
similar differences in other employment categories. In topic 13,
some respondents identified their being older as a key factor in
their decision to accept offers of COVID-19 vaccines (ACC13).
Others referenced their personal experiences of the impacts
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of now-vaccine-preventable diseases such as measles (ACC13
and ACC14).
“I’m in the older age group and it’s sensible to reduce my risk”
“Because of my age and having asthma. Also, my husband has
angina, so to help protect him.”
“I was born in the 1950s when measles, polio caused severe illness
and vaccination changed that”
“I still remember when smallpox was finally beaten. I had an older
cousin who was blind and brain damaged because her mother
caught measles when pregnant."
Participants in the lowest household income bracket (< £15,000
per annum) were less likely to accept offers of COVID-19
vaccines than any other income group (Table 1). Experiences
of financial hardship during the pandemic were reported by
20.8% (n = 944) of participants, but this was not associated
with vaccination intentions (either in the main analysis, or in
sub-analyses where [i] income was removed from the model
and [ii] where an interaction between income and hardship
was included).
Political Views
The political views of respondents were varied, with 43.7%
(n = 1,984) describing themselves as “Liberal/Left,” 23.8% (n
= 1,080) as “Conservative/Right” and 32.4% (n = 1,471) as
“Floating/Center” (Table 1). Compared to those whose political
views were central, participants on the political left (OR 0.30, 95%
CI 0.22–0.41, p < 0.001) were less likely to refuse a vaccine and
those on the political right (OR 2.05, 95%CI 1.51–2.80, p< 0.001)
were more likely to refuse a COVID-19 vaccine when offered.
DISCUSSION
The results of this online survey indicate that acceptance of
vaccines was, from the very outset of the UK’s COVID-19
vaccination campaign, likely to be very high in all regions
of the UK. Around 85% of respondents indicated that they
were willing to be vaccinated when the survey took place in
December 2020. There appeared to be no relationship between
intention to be vaccinated and geographical location, gender,
educational achievement, disability, any of a range of specific pre-
existing health conditions or experiences of having had COVID-
19 symptoms. Participants from wealthier households were more
likely to accept vaccines and previous studies have linked lower
income to higher levels of uncertainty about COVID-19 vaccines
in the UK (19) and elsewhere (20). An association between
reduced uptake of other vaccines and lower incomes has also been
seen in other studies in the United States and the UK (21, 22).
Other studies in the UK have found that older adults were
more likely to accept a COVID-19 vaccine (19, 23) but after
adjusting for covariates we found no clear association between
age and COVID-19 vaccine acceptance. We did however observe
that participants who were retired were also more likely to accept
vaccination, which may act as a proxy for the same observation
about older adults. No other employment status was associated
with intention to accept or refuse vaccination.
Despite a known increased risk of severe COVID-19 amongst
those with a number of pre-existing medical conditions (24)
we did not see any difference in COVID-19 vaccine acceptance
between those with and without doctor diagnosed comorbidities.
It is therefore possible that the overall perception of health
status is more likely to influence respondents’ attitudes toward
vaccination rather than their specific medical history. We saw an
association between vaccination and self-reported recent general
health, where those who felt that their general health was “good”
or “fair” were more likely to accept vaccines than those who
said “very good.” This fits with observations from the qualitative
analysis that some participants felt that they didn’t need to be
vaccinated because of their good general health and strength
of their immune system. Heavy current smokers indicated that
they were more likely to decline a COVID-19 vaccine than
current non-smokers. Smoking is linked to a raft of risk taking
behaviors, impaired decisionmaking and poor risk evaluations of
the future consequences of actions (25) and these considerations
could explain the much higher odds of refusing vaccines that we
observed among heavy smokers. Mangtani et al. (27) recently
showed that uptake of influenza vaccines differed by smoking
status, whilst Jackson et al. (26) highlighted that current smokers
were more likely to be undecided or unwilling to receive a
COVID-19 vaccine. The latter study also showed that smokers
were more likely to have negative feelings toward vaccines, citing
reasons that broadly echoed the concerns raised by the group of
participants who planned to refuse vaccines in this study.
The diminishment of public trust in the UK government has
been a major concern during the COVID-19 pandemic and we
have previously highlighted how generalized mistrust, concerns
about the transparent use and communication of evidence and
insights into decision-making processes affected perceptions of
the UK government’s early pandemic response (28). In the April
2020 survey, we found that 42.3% of study participants thought
that the government always or nearly always told the truth
about COVID-19 and in this survey this remained relatively
unchanged at 39.2%. Confidence in the quality of government
decision making had however changed substantially between the
two surveys. In April 2020, 52.7% of participants said that the
government was making good decisions (28), but in December
2020 just 21.7% felt this way. A poor opinion of government
decision making (and also low trust in the truthfulness of
government) was associated with increased odds of refusing
COVID-19 vaccines (Table 1). Some respondents who talked
about the government in the context of trust did however make a
clear delineation between their faith in the government and that
in the health service and/or science and scientists.
We also observed that participants who identified as having
right-wing political views were significantly less likely to accept
a COVID-19 vaccine, even after adjusting for potential socio-
demographic covariates. The opposite was true of participants
from the political left. A survey conducted in the US also found
that those whose political view was conservative/right were less
likely to accept vaccines (29). This finding may be somewhat
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surprising because the UK’s COVID-19 response was led by
a Conservative government and we might have expected that
supporters of the incumbent government would most positively
support their health initiatives. Anti-vaccination sentiments have
however been linked with support for populist political parties,
with both phenomena being “driven by similar dynamics: a
profound distrust in elites and experts” (29). The rise of populist
narratives, and particularly the UK government’s courtship of a
populist right wing during the Brexit period (2016–2021) may
therefore have led to the consolidation of political but not policy
support amongst certain sections of the Conservative electorate.
Previous behaviors and experiences with regards to utilization
of vaccines against seasonal influenza were associated with
increased uptake of COVID-19 vaccines. This finding has also
been seen in other studies in the UK (19, 23), Australia (30) and
(in some demographic groups) in the United States of America
(31). Perhaps unsurprisingly, our results also identified that
participants’ levels of generalized vaccine hesitancy and previous
refusals of offered vaccines associated with respectively 3.6- and
21-times greater odds of refusing COVID-19 vaccines, compared
to those who were confident in vaccines.
During the pandemic, the significance of so-called
“infodemics” and of misinformation, rumor and unscientific
beliefs, has been at the forefront of public debates (32).
Underlying these discussions is the assumption that hesitation
toward or refusal of public health interventions is grounded
in misconceptions or poor information. We found only scant
evidence within our corpus of free text quotes to support
concerns that intentions to refuse COVID-19 vaccines were
potentially driven by effects relating to misinformation or
pseudoscience. Instead, a key element in our respondents’
considerations was trust in the product, with responses amongst
both those who said they would and those who say they would
not take a COVID-19 vaccine gravitating around questions
about the quality and safety of the vaccines. This supports critical
insights into vaccine hesitancy which reject “knowledge deficit”
framings of the problem, recasting it instead into a question of
trust in scientific expertise (33).
Among those participants who said they would not accept
a COVID-19 vaccine, we found that their primary concerns
were highly specific to the vaccine development process, to
issues relating to the rapidity of the vaccine trials & the novelty
of mRNA-based vaccines; as well as to the relative absence
of knowledge about the long-term effects and safety including
in pregnancy and breastfeeding. Whilst the seemingly low
penetration of misinformation in our corpus of text may have
been biased downwards by the limited representativeness of our
sample, empirical social scientific research on rumors, hesitancy
and trust in medical research across different contexts has shown
similar results (34). In the context of the concerns of this study’s
participants, COVID-19 vaccine hesitancy appeared to be framed
by legitimate concerns about the perceived unavailability of
substantive scientific data to support claims that the vaccines
were safe and (possibly to a lesser degree) effective. It is notable
that one COVID-19 vaccine had received licensure in the UK at
the time of the survey and that specifically long-term safety issues
were a focus point of public discussion.
The safety of vaccines is a prevalent topic in the debate
on vaccine hesitancy (35–37). Reduced confidence may be
heightened when limited scientific data are available, for instance
in the case of investigational, experimental, and new vaccines
used during the response to epidemics (38). Some respondents
claimed that whilst they would not accept a vaccine at present,
they might possibly do so in the future, for example when there
was a better understanding of potential adverse events following
vaccination in other members of the population. The timing of
data collection is salient here, as our respondents’ reflections
show the particular considerations surrounding deployment of
a new vaccine during a health emergency. Indeed, this desire
to defer vaccination reflects similar observations made during
studies on the acceptance of a vaccine against Ebola virus in
Sierra Leone (39). Some governments even made decisions to
defer COVID-19 vaccination at the level of national policy
(40); for instance, by delaying the commencement of COVID-
19 vaccination programmes whilst observing the impacts of
programmes underway in countries with a higher burden of
disease (40).
If concerns around vaccination were very specifically related
to questions about vaccine development, then reflections on
willingness to take the vaccine amongst our respondents were
rooted in expressions of social responsibility and a vision of the
public good. Many respondents focused on the desire to return
to “normality,” to be able to see family and friends, to resume
social activities and to be able to travel again. These motives
for willingness to be vaccinated with a novel vaccine represent
a complex interaction between altruistic actions and self-interest
that have been reported by others participating in experimental
studies (41, 42).
Key limitations of this study were that it was non-
representative and that the sampling-method was not random;
meaning that the study findings are not generalisable either
in the UK or elsewhere. We caution in particular that whilst
vaccine dis- or mis-information did not appear to be a major
influencer of vaccine choice in this UK cohort, this may not
be the case in other jurisdictions. The study’s participants were
disproportionately likely to be highly educated, white and aged
over 50 years and there was very limited participation in the
18–34 age group. Ethnic minority groups are at greater risk
from COVID-19 (24, 43) and are also less likely to report
that they will accept COVID-19 vaccination (44) but these
groups were under-represented among those responding to the
survey. Facebook’s advertising policies preclude the targeting of
boosted posts to specific ethnic minority groups, and we were
therefore unable to influence the degree to which the advert
was seen by, or engaged with by members of ethnic minority
groups. The study was observational and causal links between
the outcomes and statistically associated explanatory variables
cannot be assumed. Additionally, covariates which were not
included in the study, or any that were misclassified, could
have led to residual confounding. As the study relied on self-
reported information, there was scope for response bias, although
we designed the questions to minimize this wherever possible.
Finally, whilst the STM analysis is fully reproducible using
statistical software, the assignment of topic names was performed
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manually; albeit only after a process of discussion and consensus
that included all authors of this work. Finally, we acknowledge
that the study design allowed for a large sample size which
favored a broad representation of public sentiment, but that this
may not have provided the same depth as a more comprehensive
qualitative survey.
Our embedded mixed-methods analysis highlights groups
that may be less engaged with the vaccination program and
also provides a more detailed exploration of the complex factors
and considerations that influenced decision-making among those
who planned to either accept or reject the offered vaccines.
We suggest that in the context of the COVID-19 pandemic,
levels of public complacency about SARS-CoV-2 vaccines
were very low; whilst the large scale, well organized and
equitable NHS-led deployment of vaccines in the UK meant
that convenience was high. The majority of respondents to
this survey reported on how they intended to accept offers of
vaccination, suggesting that confidence was high, regardless of
the many unknowns. The dominant theme among all topics
relating to vaccine acceptance was that there was a need to restore
normality, and for individuals to participate in the social good of
vaccination by protecting themselves, their loved ones and others
in their communities.
Reasons for refusing offered vaccines were more diverse,
but notably focussed on legitimate questions about the safety
and efficacy of vaccines, the speed of their development cycle,
whether there was a real need for a vaccination program and to
a lesser extent on whether the government and pharmaceutical
companies had hidden motivations. There was no evidence of
widespread misinformation or factors relating to an infodemic
having influenced the decisions of many participants.
Engaging with public perceptions of a newly developed
vaccine, deployed at the height of a health emergency, we
question whether the dominant narratives of vaccine hesitancy
are misconceived as primarily (or dominantly) being driven by
“fake news,” misinformation and disinformation on an epidemic
scale (infodemics). Whilst we fully recognize the importance of
combating misinformation, we propose that efforts to maintain
high levels of vaccine confidence should not neglect to contend
with legitimate concerns about the lack of transparency about
the scientific process of vaccine development. Public engagement
should therefore attend to deeper questions of (mis)trust in
science and leadership. In order to maximize uptake, the
vaccination programme should leverage the sense of altruism,
citizenship and collective responsibility that motivated many of
our participants to get vaccinated.
It should be noted that this study was conducted in December
2020, at the start of the mass vaccination campaign in the UK.
Current attitudes to vaccination may have subsequently changed,
but the aim of this paper is to contend with perceptions of a
novel vaccine being prepared for deployment at the height of
a health emergency. We reiterate the call of Scheinerman and
McCoy (author?) (45) to address these issues through effective
engagement with the public through a process of transparency,
ethical reasoning and both formal & informal deliberation (45).
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